Status:

RECRUITING

Impact of Satiating Compounds and Hypocaloric Diet on Weight, Cardiometabolic and Osteoarticular Health in Obesity

Lead Sponsor:

Clinica Universidad de Navarra, Universidad de Navarra

Conditions:

Obesity

Overweight

Eligibility:

All Genders

18-65 years

Phase:

NA

Brief Summary

The main objective of this intervention study is to evaluate the effect of satiating protein and/or fiber bar consumption on weight loss and other osteoarticular and cardiometabolic parameters related...

Detailed Description

Volunteers expressing interest in the study will undergo an initial eligibility assessment, either via telephone interview or by completing an online screening form (Google Form), to verify compliance...

Eligibility Criteria

Inclusion

  • Volunteers of both sexes between the ages of 18 and 65 years old.
  • Volunteers with grade II overweight or obesity (BMI: 27.0-39.9 kg/m2).
  • Physical examination and vital signs are normal or clinically irrelevant to the study.
  • Volunteers receiving pharmacological treatment may be included if the dosage has remained stable for at least three months prior to study initiation.
  • Individuals undergoing treatment for diabetes will be excluded.
  • Participants must be capable of understanding the study requirements, willing to provide written informed consent, and able to comply with all study procedures and timelines.
  • Body weight must have remained stable (±5%) during the three months preceding study initiation.

Exclusion

  • Presence of significant functional or structural abnormalities of the digestive system, including but not limited to congenital malformations, angiodysplasia, active peptic ulcer disease, chronic inflammatory or malabsorption disorders, hiatal hernia, or chronic gastroesophageal reflux.
  • High alcohol consumption, defined as \>14 units per week for women and \>20 units per week for men.
  • Pregnancy or lactation at the time of screening.
  • History of surgical procedures resulting in permanent alterations of the digestive system (e.g., gastroduodenostomy) or joint replacement surgery (hip or knee).
  • Diagnosis of arthritis.
  • History of any liver disease, with the exception of non-alcoholic fatty liver disease.
  • Diagnosis of any type of cancer, current cancer treatment, or history of cancer treatment within the past five years.
  • Known allergy or hypersensitivity to any component of the investigational product or to any food that could interfere with study participation and follow-up.
  • Presence of cognitive and/or psychological impairment that could affect study compliance.
  • Anticipated poor adherence or, in the opinion of the investigator, inability to comply with study procedures.
  • Engagement in night-shift work.
  • Current use of dietary supplements that may interfere with study outcomes (e.g., nutraceuticals containing compounds with potential weight loss effects).
  • Ongoing treatment for weight loss or diabetes.

Key Trial Info

Start Date :

August 20 2025

Trial Type :

INTERVENTIONAL

Allocation :

ESTIMATED

End Date :

June 30 2026

Estimated Enrollment :

144 Patients enrolled

Trial Details

Trial ID

NCT07165548

Start Date

August 20 2025

End Date

June 30 2026

Last Update

September 10 2025

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Center for Nutrition Research

Pamplona, Navarre, Spain, 31008